Showing In the Press
ADVI’s Lindsay Bealor Greenleaf told BioWorld that whether the launch interchangeable insulin biosimilars will result in lower costs for patients will be decided by PBMs.
ADVI’s Lindsay Bealor Greenleaf told BioWorld that whether the launch interchangeable insulin biosimilars will result in lower costs for patients will be decided by PBMs. Read the full article here.
Read more
ADVI’s Lindsay Bealor Greenleaf spoke to BioWorld about the latest congressional scrutiny around prescription drug list price increases and the overlooked role played by pharmacy benefit managers.
ADVI’s Lindsay Bealor Greenleaf spoke to BioWorld about the latest congressional scrutiny around prescription drug list price increases and the overlooked role played by pharmacy benefit managers. Read the full article here
Read more
ADVI’s Lindsay Bealor Greenleaf spoke to AISHealth about CMS’ recent proposal to rein in pharmacy price concessions imposed by pharmacy benefit managers
ADVI’s Lindsay Bealor Greenleaf spoke to AISHealth about CMS’ recent proposal to rein in pharmacy price concessions imposed by pharmacy benefit managers. Read the full article here
Read more
ADVI’s Lindsay Bealor Greenleaf spoke to AIS Health about a new report on PBMs & their ability to manufacture profits at the expense of patients.
ADVI’s Lindsay Bealor Greenleaf spoke to AIS Health about a new report on PBMs & their ability to manufacture profits at the expense of patients. Read the full article here
Read more